Psychedelic Companies Directory

2A Biosciences

2A Biosciences is a private company developing 5-HT2A agonists for ophthalmological and CNS-related conditions.

AbbVie (NYSE: ABBV)

In Summer 2025, the large pharmaceutical company AbbVie acquired Gilgamesh Pharmaceuticals’ lead psychedelic candidate, bretsilocin (GM-2505), in a deal valued at up to $1.2 billion. The acquisition followed a collaborative effort the pair entered in May 2024 to develop new neuroplastogens.

Through its acquisition, AbbVie became the largest pharmaceutical company to substantively enter the psychedelics field. Bretisilocin, AbbVie’s phase 2 tryptamine candidate, is being developed as a treatment for major depressive disorder (MDD).

Alexander Shulgin Research Institute

The Alexander Shulgin Research Institute (ASRI) is a drug discovery company that describes itself as “dedicated to continuing and extending the work of Dr. Alexander ‘Sasha’ Shulgin.” In 2024, ASRI licensed a library of its candidates to Negev Labs.

Algernon NeuroScience (subsidiary of Algernon Health; CNSX: AGN)

Algernon Neuroscience, a subsidiary of Algernon Pharmaceuticals, is developing AP-188, a DMT formulation being investigated as a treatment for stroke and traumatic brain injury (TBI) recovery.

Alvarius Pharmaceuticals

Alvarius says it is developing psychedelic-based candidates for substance use disorders. As of early 2026, the company appears inactive.

Amandala Neuro

Amandala was spun out of Beckley Psytech during atai Life Sciences’ acquisition. The company houses ELE-101, an IV psilocin candidate under development for major depressive disorder.

Apex Labs

Apex Labs is developing both low- (APEX-52) and high-dose (APEX-90) psilocybin for depression and PTSD. The company’s APEX-52 program is targeting approval for at-home use, while its APEX-90 program is focused on higher-dose in-clinic interventions.

Arcadia Medicine

Backed by investors including Sam Altman, Arcadia Medicine is developing empathogens, including AM-1002, a non-racemic form of MDMA for generalised anxiety disorder (GAD).

AtaiBeckley (formerly atai Life Sciences; NASDAQ: ATAI)

atai Life Sciences launched as a “hub-and-spoke platform company in 2018, an approach similar to that leveraged by non-psychedelic biotechs like Roivant. Since formation, the company has shed a number of pipeline candidates, including its early flagship candidate PCN-101 (R-Ketamine) and DMX-1001 (noribogaine). More recently, the company has brought some partially-owned assets in-house, moving away from its early decentralised model, and has slowly divested from its equity interest in psilocybin drug developer Compass Pathways.

In November 2025, the company completed its acquisition of privately-held British psychedelic drug developer Beckley Psytech. In doing so, it acquired Beckley’s BPL-003 program, an intranasal formulation of 5-MeO-DMT under development for treatment-resistant depression (TRD). Following the acquisition, the company rebranded, changing its name from atai Life Sciences to AtaiBeckley.

AtaiBeckley’s pipeline features other psychedelic candidates, including VLS-01 (DMT) and EMP-01 (R-MDMA). The company has also begun development of non-hallucinogenic candidates, including its EGX series of compounds.

B.More

B.More is a nonprofit drug development organisation that has a focus on developing a psilocybin candidate for alcohol use disorder and other substance use disorders. Its sister firm is Ceruvia.

BetterLife Pharma (OTCQB: BETRF)

BetterLife Pharma is developing BETR-001, the (6R,9R) stereoisomer of 2-bromo-LSD, as a non-hallucinogenic treatment for indications including TBI, PTSD, headache disorders, depression, and anxiety.

Bexson Biomedical

Bexson Biomedical is a private company generally focused on the development of BB106, a ketamine candidate for acute pain management and mental health indications.

Biomind Labs (PNK: BMNDF)

Biomind Labs is a Canadian company with four clinical-stage and four pre-clinical development programs. The company’s clinical pipeline is led by its BMND01 (DMT) and BMND08 (5-MeO-DMT) candidates, which are under development for TRD and Alzheimer’s, respectively.

Bright Minds Biosciences (NASDAQ: DRUG)

Bright Minds is a drug developer that is now primarily focused on the progression of its mid-stage 5-HT2C agonists. However, the company does retain at least two preclinical psychedelics-related programs targeting depression. Notably, BMB-201 is being developed as a non-hallucinogenic treatment suitable for at-home use, while BMB-202 is designed to have a shorter duration of effects relative to traditional psychedelics.

CaaMTech

CaaMTech is a psychedelics-inspired drug discovery company. Alongside its work synthesising and characterising numerous psychedelics, CaamTech has assembled a large intellectual property portfolio focused predominantly on tryptamines. In April 2025, the company announced that it had spun out Transneural Therapeutics to develop non-hallucinogenic neuroplastogens.

Cacti Therapeutics

Cacti describes itself as a biotech company developing psychedelic-derived “nociplastigens” for the treatment of chronic pain, inflammation, and opioid use disorder. As of early 2026, the company appears inactive.

Ceruvia Lifesciences

Ceruvia is developing the non-hallucinogenic LSD analog BOL-148, also known as 2-bromo-LSD, for conditions including migraine, headache disorders, and substance use disorders. Its sister firm is B.More.

Clearmind Medicine (NASDAQ: CMND)

Clearmind is developing CMND-100 (5-MeO-AI) as a treatment for alcohol use disorder (AUD). The company’s early-stage preclinical pipeline also features compounds such as 2-FDCK, 5-MAPB, and 6-APB.

Clexio Biosciences

Clexio is developing CLE-100, an oral esketamine candidate for major depressive disorder.

Compass Pathways (NASDAQ: CMPS)

Compass Pathways was among the first for-profit and publicly-traded psychedelics companies, after parlaying its work as a non-profit into a for-profit entity back in 2016. Compass is now among the largest and most mature psychedelic drug developers

The company is developing its synthetic psilocybin candidate (COMP360) for TRD, with an additional development focus on PTSD. It is expected to be the first psilocybin drug developer to file a new drug application (NDA) in late 2026.

Definium Therapeutics (NASDAQ: DFTX)

Formerly known as Mind Medicine (MindMed), Definium Therapeutics unveiled its rebrand in January 2026. The company is primarily focused on developing DT120, its phase 3 LSD candidate for generalised anxiety disorder (GAD) and MDD. Like other psychedelic drug developers, the company has emphasised that its protocol does not involve psychotherapy.

Definium is also developing R(-)-MDMA (DT402) for autism spectrum disorder (ASD), which entered Phase 2a in late 2025. Like other psychedelic drug developers, Definium has shed candidates along the way. Most notably, it shelved its non-hallucinogenic ibogaine derivative 18-MC program in 2022.

The company has also undergone a pronounced professionalisation of its leadership over the years, with its early capital-markets-oriented founders eventually giving way to clinically-focused executives. This process appears to have culminated in its 2026 rebrand.

Delix Therapeutics

Delix is one of the early-movers in the ‘non-hallucinogenic’ development landscape. Since its founding in 2019, the company has worked to discover and develop new ‘neuroplastogens’ such as DLX-001 (Zalsupindole) and DLX-007 (Tabernanthalog) for various neurological indications.

DemeRx

DemeRx is developing noribogaine (DMX-1001) for alcohol use disorder and other substance use disorders. In 2019, (then) atai Life Sciences and DemeRx established a joint venture to develop ibogaine and its less psychoactive metabolite noribogaine. However, in 2023 atai shelved the noribogaine program, opening the door for DemeRx to restart its own in-house development efforts.

Diamond Therapeutics

Toronto-based Diamond Therapeutics is a psychedelic drug developer progressing low-dose psilocybin for demoralisation.

Elkedonia

Elkedonia is developing non-hallucinogenic neuroplastogens for neuropsychiatric disorders.

Emyria (ASX: EMD.AX)

Emyria is an Australian psychedelic care delivery and drug development company. The company offers in-clinic psilocybin and MDMA therapy, within the framework of the country’s limited rescheduling of the drugs. In addition to treatment delivery, Emyria says that it is developing new “pro-social” compounds.

Empyrean Neuroscience

British company Empyrean aims to harness genetic engineering to modify the genomes of fungi and plants, including Psilocybe cubensis and Tabernanthe iboga, to enable the production of novel molecules for the treatment of neuropsychiatric and neurologic disorders. As of 2026, the company appears inactive.

Entheos Labs

Entheos is developing botanically-derived neuroplastogens for a number of psychiatric disorders. The company’s lead candidate, ET-01, is a natural product derivative that it anticipates will be safer and more tolerable.

Entropy Neurodynamics (PNK: TYPTF)

Entropy, formerly Tryp Therapeutics, is developing IV psilocin for chronic pain and eating disorders.

Equulus Therapeutics

Equulus is working to develop non-hallucinogenic drug candidates for substance use disorders and PTSD. Its lead candidate, EQL-101, is an ibogaine analog that it hopes will be devoid of ibogaine’s hallucinations and cardiotoxicity. The company is also investigating an MDMA analog and a fenfluramine-class agent.

Enveric Biosciences (NASDAQ: ENVB)

Enveric is developing EB-003, a non-hallucinogenic neuroplastogen. The company’s lead preclinical asset is being investigated as a potential treatment for PTSD, TRD, and GAD.

Eywa

Eywa is a Uruguayan company focused on the production of psychedelic active pharmaceutical ingredients (APIs).

Filament Health (PNK: FLHLF)

While most psychedelic drug developers are focused on synthetic compounds, Filament Health has built its business around the development and manufacture of ‘naturally-derived’ psychedelic drug candidates. The company produces GMP botanical psilocybin and supplies its drug products for use in a number of clinical trials.

Five Discovery

Five Discovery is a developer of non-hallucinogenic neuroplastogens that launched in February 2026. The company intends to target neurodegenerative diseases and brain injury.

Freedom Biosciences

Freedom is developing FREE001, a combination drug product being investigated for TRD. The company aims to extend the antidepressant effect of ketamine by combining it with temsirolimus, an mTOR inhibitor that is marketed for renal cell carcinoma. Freedom Biosciences was co-founded by prominent ketamine researcher John Krystal.

GH Research (NASDAQ: GHRS)

Like Compass Pathways, GH Research is essentially a single-candidate drug developer. The company is focused on the potent, short-acting psychedelic 5-MeO-DMT, which has the international nonproprietary name ‘mebufotenin’.

The company is primarily pursuing an inhaled formulation, which it calls GH001, for TRD. However, GH’s approach has come with challenges. Notably, in 2023 the FDA placed the IND for GH001 on clinical hold, requesting additional inhalation toxicology studies and further device design verification information. After a multi-year process to address those requirements, the FDA lifted the clinical hold in January 2026, enabling U.S. subject enrollment. GH Research now plans to initiate its phase 3 program in the second half of 2026. The company is simultaneously developing GH002, an IV formulation of 5-MeO-DMT.

Gilgamesh Pharma

Founded in 2019, Gilgamesh Pharma (formerly Gilgamesh Pharmaceuticals) is developing several candidates, including Blixeprodil (GM-1020), an oral NMDAR antagonist, and GM-3009, a ‘safer ibogaine analog’ which is said to be less cardiotoxic than ibogaine. In 2024, the company received $19 million from NIDA to develop its GM-3009 program. Gilgamesh has also partnered with AbbVie on its non-hallucinogenic neuroplastogen program GM-5022 program.

In 2025, Gilgamesh Pharmaceuticals sold bretisilocin (GM-2505), its lead short-acting tryptamine candidate, to AbbVie for up to $1.2 billion. Following the acquisition, Gilgamesh Pharma was spun out to house its other aforementioned drug development programs.

Helus Pharma (NASDAQ: HELP)

In January 2026, the psychedelic drug developer Cybin completed a rebrand to Helus Pharma. Since its formation in 2019, the company has been developing deuterated forms of classical psychedelics. Following its 2023 acquisition of Small Pharma, the company’s clinical pipeline features deuterated versions of psilocybin (HLP003) and DMT (HLP004) for MDD and GAD, respectively.

Additionally, under its HLP005 program, Helus is said to be developing novel tryptamine and phenethylamine candidates.

Incannex Health (NASDAQ: IXHL)

Incannex is an Australian drug developer that is primarily focused on cannabinoids, though it is also developing psilocybin for GAD (PSX-001). Following the completion of a phase 2 study in August 2025, Incannex has begun preparation to advance PSX-001 into late-stage development.

Johnson & Johnson (NYSE: JNJ)

Through its $14.6 billion acquisition of Intra-Cellular Therapies, Johnson & Johnson brought in-house ITI-1549, a non-hallucinogenic neuroplastogen, though it is not thought to be a major strategic focus for J&J.

Kasvu Therapeutics

Kasvu is a Finnish company exploring non-hallucinogenic neuroplastogens for neuropsychiatric and neurodegenerative conditions, including Alzheimer’s and Parkinson’s.

Ketabon

Ketabon is developing KET01, an oral prolonged-release formulation of ketamine, for treatment-resistant depression.

Küleon Bioscience

Küleon is exploring the use of serotonergic drugs for neuropsychiatric disorders. In 2025, the company was awarded a $2 million National Institute on Alcohol Abuse and Alcoholism (NIAAA) grant to fund the development of its serotonin 5-HT2C agonist candidate KB-128 as a treatment for alcohol use disorder.

Lophora

Backed by Novo Nordisk’s BioInnovation Institute Foundation and Danish state investment funds, Lophora is advancing its lead candidate LPH-5, a phenethylamine-derived 5-HT2A receptor agonist, through Phase I studies.

Mindstate Design Labs

Mindstate is a drug discovery and development company leveraging its AI-powered ‘Osmanthus’ platform to investigate neurotransmitter interactions and resulting emotional states. This data is said to inform the company’s drug development efforts. Mindstate’s lead non-hallucinogenic asset, MSD-001, is an oral formulation of 5-MeO-MiPT that the company hopes to combine with other substances to treat various psychiatric indications. The company’s preclinical pipeline also includes other early candidates from its MSD-001 and MSD-X02 programs.

MSICS Pharma

MSICS is developing psilocybin (MSX-06) for treatment-resistant depression and OCD.

MycoMedica Life Sciences

MycoMedica is developing low-dose psilocybin (MLS101) for a variety of conditions, including premenstrual dysphoric disorder, obsessive compulsive disorder, and opioid use disorder.

Negev Labs

Negev Labs is a venture studio funding the discovery and development of neuroplastogens. In 2024, the studio emerged from stealth to announce that it had licensed a library of candidates from the Alexander Shulgin Research Institute and acquired (then) Beckley Psytech’s ophthalmology program. In collaboration with the Hadassah Brain Labs Center for Psychedelic Research, Negev is developing HBL20017, a non-hallucinogenic compound, as a treatment for OCD.

Neurala Biosciences

Neurala is an Australian company developing its DMT-harmala candidates NBX-100 and NBX-200 for substance use disorders and major depressive disorder, respectively. The company’s preclinical pipeline also includes its NBX-300/400 “sub-perceptual” and “sub-psychedelic” programs.

Neurocentrx Pharma

Neurocentrx is developing an abuse-deterrant oral ketamine candidate, NRCx-201, for bipolar depression.

NRx Pharmaceuticals (NASDAQ: NRXP)

NRx is developing a preservative-free form of IV ketamine (NRX-100) in patients with treatment-resistant depression who may have suicidality. The company has also filed a citizen petition seeking the removal of benzethonium chloride, the preservative used in current commercial IV ketamine products, from the market entirely, on the basis that the compound is not generally recognised as safe.

Ocellaris

Ocellaris is developing neuroplastogens for neuropsychiatric disorders.

Optimi Health (OQX: OPTHF)

Optimi is a licensed GMP manufacturer of MDMA and naturally-derived psilocybin drug products.

Otsuka (TYO: 4578)

Otsuka’s engagement with the psychedelics field is notable. In 2020, the company’s McQuade Center for Strategic Research and Development participated in Compass Pathways’ $80 million series B round. In 2023, Otsuka acquired Canadian psychedelic drug developer Mindset Pharma for $80 million, bringing Mindset’s portfolio of novel analogs in-house. Today, the company’s CNS approach appears defined by ‘novel serotonergic agonists’, its preferred term for psychedelics and related drugs.

The relationship between Otsuka and the psychedelics field has not been one-directional. Notably, Compass Pathways’ CEO Kabir Nath previously led Otsuka’s North American business.

PharmAla Biotech

PharmAla is a drug discovery company focused on empathogens, including MDMA and related analogs. The company also has agreements with manufacturers to produce GMP MDMA and psilocybin, which it sells or provides to researchers and clinicians.

Psilera

Psilera is focused on developing its lead non-hallucinogenic psychedelics-based candidate PSIL-006 for neurological disorders, including frontotemporal dementia. In early 2025, it entered into an agreement with AtaiBeckley (formerly atai Life Sciences), through which the company licensed all rights to its DMT intellectual property.

Psy Therapeutics

Psy Therapeutics is a preclinical drug discovery company developing candidates for CNS disorders such as chronic pain.

Psyence BioMedical (NASDAQ: PBM)

Psyence describes itself as a biotech company focused on developing “botanical psilocybin-based psychedelic medicines.”

Psygen Labs

Psygen is a manufacturer of psychedelics and neuroplastogens.

Reconnect Labs

Reconnect is a Swiss company developing both psychedelic and non-psychedelic candidates. The company is developing 5-MeO-DMT (RE02) for generalised anxiety disorder and a DMT-harmine formulation (RE01) for cocaine use disorder.

Remedi Therapeutics

Remedi says it is developing a combination of DMT and an MAOI or RIMA for neuropsychiatric indications.

Resilient Pharmaceuticals (formerly Lykos Therapeutics, MAPS PBC)

Resilient, formerly known as Lykos Therapeutics and prior to that MAPS Public Benefit Corporation, is the progeny of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). It was founded in 2014 to develop and commercialise MDMA as an FDA-approved treatment for PTSD.

Having closed a $100+ million Series A in January 2024 and submitting its NDA the following month, things were looking rosy for the company in early 2024. But the wheels began coming off in March 2024, when the independent cost-effectiveness group ICER published a draft evidence report that deemed the clinical evidence ‘insufficient,’ picking methodological holes in the company’s Phase 2 and 3 trials. An FDA advisory committee corroborated many of those concerns in June 2024, voting nearly unanimously against approval. On August 9, 2024, the FDA issued a Complete Response Letter (CRL), which was later made public.

Lykos subsequently announced layoffs and leadership changes. In early 2025, new funders recapitalised the company, which is understood to be preparing to resubmit the application.

Reset Pharma

Reset is investigating psilocybin (RSTP-100) as a treatment for demoralisation syndrome. As of early 2026, the company appears to be inactive.

Reunion Neuroscience

Reunion spun out from Field Trip Health in 2022. The company’s lead candidate, RE104 (Luvesilocin), is being developed as a treatment for postpartum depression (PPD), as well as adjustment disorder and generalised anxiety disorder. Additionally, the company is developing RE245, a non-hallucinogenic drug candidate. In February 2026, the company announced that the FDA had awarded its postpartum depression program breakthrough therapy designation.

Rivo Bio

Rivo is a discovery-stage company working to develop psychedelic-inspired therapeutics for neuropsychiatric and neurodegenerative disorders.

Seaport Therapeutics

Seaport launched in April 2024 with a $100M Series A to leverage its Glyph^TM prodrugging platform to advance various neuropsychiatric drugs. While psychedelics-related compounds are not the company’s primary focus, Seaport’s preclinical pipeline features SPT-348, a 2-bromo-LSD prodrug being developed for headache disorders and TRD.

Shortwave Life Sciences

Shortwave is a British company developing psilocybin for anorexia nervosa.

Solvonis Therapeutics (LON: SVNS)

In May 2025, Solvonis Therapeutics acquired psychedelic drug developer Awakn Life Sciences, a company that began its life in 2020 as a ketamine clinic chain. Following the acquisition, Solvonis’s pipeline is led by SVN-001, a phase 3 program focused on developing ketamine as an approved treatment for severe AUD in the UK and EU. At the same time, Solvonis is advancing other candidates including SVN-002 (esketamine), SVN-SDN-14, and SVN-015 for a range of psychiatric indications.

Soneira Bio

Soneira is developing an ibogaine-magnesium combination (SON-001) for traumatic brain injury. The company emerged in Summer 2024 with funding from Google co-founder Sergey Brin.

Tactogen

Tactogen is developing ‘gentler’ MDMA-like molecules (empathogens) for various conditions, including alcohol use disorder and anorexia nervosa. The company is also looking to trial a combination of MDMA and citalopram in PTSD.

Tasman Therapeutics

Tasman is a spin-out of New Zealand pharmaceutical firm Douglas. It’s developing R-107, an oral extended-release ketamine tablet, for treatment-resistant depression and other depressive disorders.

Terran Biosciences

Aside from the non-psychedelic candidates it is developing, Terran has amassed a substantial psychedelics-related patent estate, as we have covered.

Transcend Therapeutics

Transcend is developing TSND-201 (methylone) for PTSD, generalised anxiety disorder, and major depressive disorder. The company anticipates advancing its PTSD program into Phase 3 trials in 2026. Transcend’s preclinical pipeline is also said to feature new analogs, though their status is still unknown.

Transneural Therapeutics

In April 2025, CaaMTech announced that it had spun out Transneural Therapeutics, a company focused on developing non-hallucinogenic neuroplastogens for neuropsychiatric and neurodegenerative disorders. The company’s pipeline features two preclinical leads, TN-001 and TN-002. Notably, part of the company’s intellectual property portfolio was assigned (first to CaaMTech) from the now-defunct Onsero Therapeutics, a company previously affiliated with the work of Bryan Roth.

Usona Institute

Usona is a nonprofit psychedelic drug developer focused primarily on psilocybin and 5-MeO-DMT. The company’s Phase 3 psilocybin program is focused on major depressive disorder. The organisation presumably hopes its single Phase 3 trial will be sufficient to secure approval.

Xylo Bio

Xylo is developing non-hallucinogenic 5-HT2A agonists for mental and behavioural health disorders, as well as chronic pain. The company was founded in Australia but has since established a U.S. presence.

As noted above, the industry extends beyond drug development, with other categories including:

Clinics & Trial Sites: A number of companies are focused on the delivery of psychedelic therapies, primarily through ketamine and esketamine (Spravato) clinics. These include Stella Mental Health, which expanded its clinic footprint through its acquisition of Field Trip Health’s U.S. assets and Numinus’ Utah clinics, and Heading Health, which operates ketamine and Spravato clinics in Texas. Journey Clinical operates in a slightly different niche, providing a platform that enables existing therapists to offer ketamine-assisted therapy by pairing them with licensed prescribers.

A smaller number of companies have also established themselves as dedicated psychedelics clinical trial sites. These include Sunstone Therapies, which conducts psychedelic-assisted therapy trials out of its Maryland facility, and Clerkenwell Health, which operates in the UK.

Benefits Providers: On the benefits side, Enthea and TARA Mind are working to make psychedelic-assisted therapies availableƒ as employer-sponsored benefits, currently offering coverage for ketamine-assisted therapy with plans to expand to cover other psychedelics should they receive regulatory approval.

Training Providers: Several organisations offer training for therapists and facilitators looking to work with psychedelic medicines. Fluence, for example, has trained more than 8,000 providers and possesses a state license to train Oregon’s psilocybin facilitators. Additionally, the California Institute of Integral Studies offers a Psychedelic-Assisted Therapies and Research Certificate program to prepare therapists.

Technology: A small number of technology companies are building tools to support the broader industry. For example, Osmind has developed an electronic health record platform tailored to interventional psychiatry providers, including those who offer ketamine and psychedelic therapies. mPathic uses AI to provide therapy session oversight in clinical trials, and to assist sponsors in monitoring study therapists’ adherence to protocols.

State Program Operators: In addition to the companies listed above, the regulation of psilocybin services in states like Oregon and Colorado has given rise to a nascent market of service and healing centres, cultivators and manufacturers, testing laboratories, and state-approved training schools operating under their respective regulatory frameworks.